Latest in Cardiology from ACC.org

• SOGALDI-PEF: Baseline Renin Levels Predict BP Treatment Effect
  Patients with low plasma renin levels had a more pronounced blood pressure (BP) reduction with spironolactone/dapagliflozin vs. dapagliflozin alone, in addition to seeing a more favorable impact on cardiovascular structure and function, while aldosterone levels exhibited no predictive value in treatment response...
• Eagle’s Eye View: Impact of Semaglutide And Survival Outcomes In Patients With T2D and CKD
  In this week’s View, Dr. Eagle highlights several noteworthy developments shaping cardiovascular and renal care.
• First-Ever Guideline Addresses CKM Syndrome
  The new 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome is the first ever to address the "interrelated condition characterized by the interconnections among metabolic risk factors (including obesity and type 2 diabetes)...
• Optimizing Dual Antiplatelet Therapy in Patients With Diabetes and Multivessel Disease Undergoing PCI: The TUXEDO-2 Trial
  The TUXEDO-2 (Ultrathin Strut vs. Xience in a Diabetic Population With Multivessel Disease 2—India Study) trial demonstrated that among patients with diabetes mellitus and multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI)...
• ACCEL Lite: Key Take-Home Messages From the 2025 Sports Cardiology Guidelines
  In this interview, Alison L. Bailey, MD, FACC and Aaron Baggish, MD, FACC examine the latest sports cardiology guidelines.